Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA)
given in combination with trametinib (MEKINIST) in patients who have progressed on prior
melanoma therapy.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute